In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 684 ( 2023-02-22)
Abstract:
Antiretroviral drugs are essential components of the HIV-1 treatment toolbox. Although these drugs are effective at controlling viral load in individuals living with HIV-1, they do not represent a curative strategy. Interestingly, some non-nucleoside reverse transcriptase inhibitors also kill HIV-1 infected cells, but require a high drug concentration to do so. With this secondary activity in mind, Balibar et al . discovered reverse transcriptase inhibitors that, in addition to retaining conventional antiviral function, also promote selective cytotoxicity of HIV-1 infected cells at clinically meaningful concentrations. These targeted activator of cell kill (TACK) molecules were able to kill HIV-1 infected CD4+ T cells isolated from people living with HIV-1, supporting further clinical development of this strategy. —CM
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abn2038
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023
detail.hit.zdb_id:
2518839-2
detail.hit.zdb_id:
2518854-9
Permalink